CYCCP

Cyclacel Pharmaceuticals, Inc. - 6% Conver…

10.90 USD
+3.06 (+39.03%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cyclacel Pharmaceuticals, Inc. - 6% Conver… stock is up 62.69% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 18 June’s closed higher than May.

About Cyclacel Pharmaceuticals, Inc. - 6% Conver…

Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.